People Who Have Had COVID-19 More Likely to Develop Cardiovascular Disease: New Report Highlights the Need to Refocus on Cardiovascular Care

Daiichi Sankyo Europe Company, Limited (hereafter, Daiichi Sankyo Europe) has today announced findings from a new report that confirms people who have tested positive for COVID-19 face higher risks of multiple forms of cardiovascular disease (CVD).¹ Additional findings show the health burden of CVD is expected to growdue to the long-term implications of COVID-19, highlighting the need to prioritise care for the CVD patient community across European healthcare systems.¹

The editorially independent report, published by Economist Impact and sponsored by Daiichi Sankyo Europe, reviewed evidence available to uncover the impact that COVID-19 has had on existing CVD patients, the delivery of cardiovascular care and the implications of ‘long COVID’ for healthcare systems in the future. With a focus on Western European regions – in particular France, Germany, Italy, Spain and the UK – the key findings of the report build on the available evidence and discussions with experts in cardiology, neurology and public health to identify areas where improvements could be made to address the growing needs of the CVD community.

In 2020, more than 60 million people were living with CVD in the European Union, and close to 13 million new cases were diagnosed that year.² The prevalence of underlying lifestyle risk factors such as high cholesterol and blood pressure, low physical activity, obesity and diabetes, has escalated over recent decades.³ The risk of developing CVD also increases with age, and as Europe’s population continues to get older, with 155 million Europeans predicted to be over 65 by 2040, the incidence of CVD is set to increase dramatically.⁴ This is likely to be further exacerbated by the COVID-19 pandemic due to the link between infection and the development of CVD, and yet 80% of premature heart disease and strokes are preventable, demonstrating an urgent need to address this healthcare crisis.^1,5

The impact of the virus on CVD-related risks

In addition to the rising prevalence of CVD risk factors, the Economist Impact report confirms that people who have tested positive for COVID-19 are at even greater risk of experiencing CVD and related health events such as heart failure, myocardial infarction, stroke, and arrythmia.¹

The Economist Impact report also suggests that there has been substantial under-reporting of deaths due to COVID-19 globally. By January 2022 it was approximated that there were 18.8 million more lives lost during the pandemic than would be expected, higher than the 5.44 million deaths attributed directly to COVID-19 by December 2021.¹ These additional deaths will include those directly due to un-detected COVID, but also deaths due to other causes, where the conditions responsible were exacerbated or caused by COVID itself or by the difficulties in accessing care during the pandemic. Such conditions are likely to include CVD.

The implications of the pandemic response for the CVD community

The report also uncovers the indirect implications of COVID-19 on healthcare systems and CVD care. The limited capacity of overworked health systems, combined with patient fear of exposure to the virus, has meant that cardiovascular care has been reduced at every level, in turn increasing mortality in the short-term as well as driving longer-term risk.¹

According to findings, this phenomenon has continued over the medium-term; nearly a year after the pandemic began, the World Health Organization still reported widespread disruption in blood-pressure management and emergency cardiovascular treatment.¹ The research conducted by Economist Impact found that this disruption has taken varying forms at different levels of care: from the unavoidable lack of emergency services and risk factor management to delays in CVD diagnosis.¹

The knock-on effects of ‘long COVID’

‘Long COVID’ describes the still poorly understood, but seemingly common, consequence of COVID-19 infection.¹ Research suggests that common manifestations of long COVID, such as shortness of breath and fatigue, are associated with greater risk of CVD events including heart failure and heart attack.¹ Commenting on the report, Dr Amitava Banerjee, Consultant Cardiologist and Professor of Clinical Data Science at University College London, explained “We are only scratching the surface when it comes to the long-term impact of COVID-19 on CVD, with more data likely to emerge over time.”

The report findings further indicate that the challenges arising from long COVID could increase CVD burden in both the short- and medium-term, calling for preventative strategies to be implemented to align with an evolving healthcare landscape. Dr Banerjee concluded, “As clinicians we are seeing people present at much more advanced stages of CVD, meaning that their care is much more challenging and favourable outcomes are less likely. To prevent fatal events and improve outcomes for patients, we must place a greater focus on identifying risk factors and detecting CVD symptoms early. Through doing this we can also alleviate the strain on already burdened healthcare systems.”

The pressing urgency to refocus efforts on CVD

While the acute pandemic crisis demanded immediate attention and resources, the Economist Impact report demonstrates the pressing urgency for healthcare systems to refocus efforts on addressing the unmet needs of CVD as Europe’s leading cause of death.¹ A renewed focus on prevention, symptom detection and identification of risk factors could reduce implications of future CVD burden.

Commenting on the report, Oliver Appelhans, Head Commercial Operations, Head Affiliate & Partner Management Specialty Medicines, Daiichi Sankyo Europe explained, “Now, more than ever, we must address the enormous impact of CVD in Europe and how it has been exacerbated by the COVID-19 pandemic.

He continued, “As an industry we have an important role to play in addressing the needs of the medical community and help protect people from CVD. At Daiichi Sankyo Europe, we remain committed to working closely with the healthcare community and industry partners to support better care - placing prevention at the centre of our efforts.”

ENDS

About Daiichi Sankyo Europe

Daiichi Sankyo Europe is dedicated to creating new modalities and innovative medicines by leveraging our world-class science and technology for our purpose “to contribute to the enrichment of quality of life around the world.” In addition to our current portfolio of medicines for cancer and cardiovascular disease, Daiichi Sankyo Europe is primarily focused on developing novel therapies for people with cancer as well as other diseases with high unmet medical needs. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation to realize our 2030 Vision to become an “Innovative Global Healthcare Company Contributing to the Sustainable Development of Society.”

For more information, please visit www.daiichi-sankyo.eu.

About cardiovascular disease

Cardiovascular diseases (CVDs) are a group of disorders of the heart and blood vessels, including coronary heart disease, cerebrovascular disease, rheumatic heart disease and other conditions. In 2020, more than 60 million people were living with CVD in the European Union, and close to 13 million new cases were diagnosed that year.²

More than four out of five CVD deaths are due to heart attacks and strokes, and one third of these deaths occur prematurely in people under 70 years of age.⁶ Despite this, 80% of premature heart disease and strokes are preventable.⁶

About COVID-19

The COVID-19 (coronavirus) pandemic is an ongoing global pandemic of an infectious respiratory disease caused by the SARS-CoV-2 virus.⁷ The novel virus was first identified in December 2019, with the World Health Organization (WHO) declaring a Public Health Emergency of International Concern in January 2020 and a pandemic in March 2020. Since December 2019 and as of March 2022, there have been 470,223,960 confirmed cases worldwide and 199,898,394 confirmed cases in Europe.^8,9

References

---

¹ Economist Impact. Links between covid-19 and cardiovascular disease: Seeing the warning signs and preparing for a healthier future. Available at: https://impact.economist.com/perspectives/healthcare/covid-and-cardiovascular-disease. Last accessed April 2022.
² European Society of Cardiology. Fighting cardiovascular disease – a blueprint for EU action. June 2020. Available at: https://www.escardio.org/static-file/Escardio/Advocacy/Documents/2020%20ESC-EHN-blueprint_digital%20edition.pdf. Last accessed April 2022.
³ European Society of Cardiology. Fact Sheets for Press – CVD in Europe and ESC Congress figures. Available at: https://www.escardio.org/The-ESC/Press-Office/Fact-sheets. Last accessed April 2022.
⁴ Cardiovascular Disease in Europe. A Call-to-Action 2019–2024. MedTech Europe. Available at: https://www.medtecheurope.org/wp-content/uploads/2019/10/MedTech-Europe-Cardiovascular-Disease-in-Europe-Call-to-Action-August2020.pdf. Last accessed April 2022.
⁵ World Health Organization. Europe Cardiovascular Diseases statistics. Available at: https://www.euro.who.int/en/health-topics/noncommunicable-diseases/cardiovascular-diseases/data-and-statistics. Last accessed April 2022.
⁶ World Health Organization. Cardiovascular diseases. Available at: https://www.who.int/health-topics/cardiovascular-diseases#tab=tab_1. Last accessed April 2022.
⁷ World Health Organization. Coronavirus disease (COVID-19) pandemic. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019. Last accessed April 2022.
⁸ European Centre for Disease Prevention and Control. COVID-19 situation update worldwide, as of week 11 updated 24 March 2022. Available at: https://www.ecdc.europa.eu/en/geographical-distribution-2019-ncov-cases. Last accessed April 2022.
⁹ World Health Organization. COVID-19 situation in the WHO European Region. Available at: https://who.maps.arcgis.com/apps/dashboards/ead3c6475654481ca51c248d52ab9c61. Last accessed April 2022.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220509005676/en/

Contact information

Media contact

Dr. Wolfgang Schiessl
Daiichi Sankyo Europe GmbH
Director PR and Portfolio Communications, Specialty Medicines
+49 151 1714 7317